Total Cost of Ownership for High-Value Medical Equipment

Start with the landed cost rather than the ex-works or list price. For imported equipment that means customs duty, clearing and forwarding, inland transport, insurance in transit, and the tax that a hospital largely cannot recover as credit. Vendors quote on different bases and a comparison that mixes them is meaningless. Insist that every bidder restates the offer on a single delivered-and-installed-at-site basis before the committee sees it.

Then add the things that are technically the vendor's scope but practically yours: unloading and rigging for heavy items, temporary structural work if the equipment cannot pass through existing doors, and the crane hire that nobody remembers until the delivery is at the gate. For anything in the several-tonne class, ask the vendor for the delivery route survey in writing before signing, not after.

Finally, capture the acquisition-adjacent commitments. Applications training for how many operators and for how many days, the warranty period and precisely what it excludes, the price at which the service contract will be available after warranty and for how long that price is held, and the guaranteed spares availability period. The last two determine most of the lifetime cost and are far easier to negotiate before award than after.

Site readiness is where capital projects overrun. A CT or MRI installation carries civil work, radiation shielding designed and certified to the requirements the Atomic Energy Regulatory Board applies through its licensing process, an RF cage for magnetic resonance, chilled water or dedicated air conditioning, and a room layout that satisfies both the vendor's specification and the regulator's. None of this is in the equipment quotation and all of it is on your capital budget.

Power is the line most often underestimated. High-value equipment typically needs a dedicated feeder, an isolation transformer, a correctly sized UPS with a battery bank replaced every few years, earthing to a specified resistance, and generator backup with a transfer time the equipment will tolerate. The recurring cost of a battery bank replacement across a ten-year life is a real number and it belongs in the model.

Then there are the licence and approval costs with their own timelines: AERB licensing for radiation-emitting equipment through the eLORA process, a radiological safety officer where required, radiation surveys, and periodic quality assurance testing. These are not merely fees. They are calendar time, and a machine that sits commissioned but unlicensed is depreciating without earning. Build the approval timeline into the payback calculation rather than assuming go-live at delivery.

For analysers, catheterisation labs, dialysis machines and much of endoscopy, the consumable stream is the dominant lifetime cost and the vendor knows it. Closed-system platforms that accept only the manufacturer's reagents or cartridges convert your equipment decision into a decade-long consumable contract, and the price of that contract after the first two years is where the vendor's return actually lives.

Model this explicitly. Take your realistic annual volume, apply the quoted consumable price, and then apply an assumed annual escalation, because a contract silent on escalation is a contract where escalation is at the supplier's discretion. As an illustrative example only: on a closed platform where consumable spend in year one equals a quarter of the capital cost, the consumable stream over a seven-year life will exceed the machine several times over, and a small difference in per-test price outweighs a large difference in capital price.

The negotiating consequence is that consumable pricing, escalation caps and the treatment of controls, calibrators and quality control material belong in the capital tender, not in a separate conversation a year later. Once the machine is installed and your laboratory has validated its methods on it, your negotiating position on consumables is materially weaker than it was the day before award.

Service cost is not flat. It is typically low or zero during warranty, moderate in the comprehensive contract years, and rising towards end of life as parts become scarce and the vendor starts steering you towards replacement. Model it as a curve rather than as a single annual figure multiplied by ten, and ask the vendor to quote the post-warranty contract for each of the years you intend to run the equipment.

Decide deliberately between comprehensive and non-comprehensive cover, and understand what each excludes. Comprehensive contracts usually carve out consumable-like parts, detector or tube replacements above a stated value, and damage attributed to power quality or user handling. Those carve-outs are precisely the failures that cost most. A contract that excludes the X-ray tube on a CT is not a comprehensive contract in any sense a hospital would recognise.

Then add the parts you should hold locally. For equipment where a single failure stops a revenue-earning service, a small consignment of critical spares held on site or at the vendor's regional depot with a contractual response commitment is worth its carrying cost. Your existing equipment register and maintenance history should tell you which parts those are; if it does not, that is itself a finding about the register.

Two costs are usually missing from hospital capital models, and they are the two that most often decide whether an investment worked. The first is the cost of downtime: when the machine is unavailable, cases are deferred, referred out or cancelled, and there is a contribution loss per hour that your finance team can estimate from the service's own tariff and case mix. Multiply that by expected annual downtime hours and it becomes a comparison variable between vendors with different service networks.

The second is utilisation, which sits in the denominator of every per-case cost you will ever quote. A machine costing the same as another but running at half the case volume has double the cost per case, and the difference usually comes from scheduling, operator availability and reporting turnaround rather than from the equipment. Before approving a machine, ask what specific operational change will produce the volume in the business case, and who owns that change.

Track both after installation. A monthly view of case volume against the business case projection, uptime against contracted uptime, and consumable cost per case will tell you within two quarters whether the investment is behaving as approved. HealUDoc equipment and utilisation records can hold the maintenance history and the case counts against the same asset, so the post-approval review is a report rather than a reconstruction from two departments' files.

A capital paper that runs to thirty pages of specification and one page of financials will be approved on the wrong basis. Invert it. Lead with the lifetime cost comparison, the volume assumption the case depends on, the payback under a base case and a pessimistic case, and the three risks most likely to break it. Put the technical specification in an annexure for the people who need it.

State the assumptions as assumptions and show a downside. A business case built on the vendor's throughput projection with no sensitivity analysis invites either rejection or, worse, approval followed by an uncomfortable review in year two. Show what happens if volume comes in materially below plan, if the service contract escalates faster than assumed, or if the licensing timeline slips a quarter. Boards approve honest cases with visible risk more readily than optimistic ones.

Finally, commit to a post-implementation review at a stated date with stated measures, and actually hold it. The discipline of knowing that the same committee will see the same numbers in eighteen months changes how the case is written in the first place. It is also the only mechanism that improves the quality of the next capital paper, because a hospital that never reviews its equipment decisions never learns which of its assumptions are systematically wrong.